When CTLA-4 engages with its ligands, CD80 and CD86, similarly to CD28, the coinhibitory response will be activated and the tumor cell will escape the host immune surveillance system (Rowshanravan et al., 2018; Xu et al., 2018). The gene discussed is CTLA4; the disease is neoplasm.